



- (51) **International Patent Classification:**
C12N 15/85 (2006.01) *A61K 35/17* (2015.01)
- (21) **International Application Number:**
PCT/US2024/015017
- (22) **International Filing Date:**
08 February 2024 (08.02.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/483,814 08 February 2023 (08.02.2023) US
- (71) **Applicant:** **CLADE THERAPEUTICS, INC.** [US/US];
201 Brookline Avenue, Suite 1002, Boston, Massachusetts
02215 (US).
- (72) **Inventors:** **HEINZE, Dar Mikael**; c/o Clade Therapeu-
tics, Inc., 201 Brookline Avenue, Suite 1002, Boston, Mass-
achusetts 02215 (US). **WELSTEAD, Gordon Grant**; c/
o Clade Therapeutics, Inc., 201 Brookline Avenue, Suite
1002, Boston, Massachusetts 02215 (US).
- (74) **Agent:** **ANDERSON, Stephen G.** et al.; c/o Greenberg
Traurig, LLP, One International Place, Suite 2000, Boston,
Massachusetts 02110 (US).

- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** CD4⁺ AND CD8⁺ SINGLE POSITIVE T CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME




FIG. 1

(57) **Abstract:** Provided herein are cell and matrix compositions for the production of single positive T cells, such as CD4⁺ single positive T cells or CD8⁺ single positive T cells. Various methods for the generation of T cells by differentiation of stem cells are also provided. Further provided herein are methods of treating a disease or a condition in a subject, including, but not limited to cancer and autoimmune diseases.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*